Research and Education Department, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou 310022, Zhejiang Province, China.
Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230000, Anhui Province, China.
World J Gastroenterol. 2024 Feb 28;30(8):833-842. doi: 10.3748/wjg.v30.i8.833.
The population of non-alcoholic fatty liver disease (NAFLD) patients along with relevant advanced liver disease is projected to continue growing, because currently no medications are approved for treatment. Fecal microbiota transplantation (FMT) is believed a novel and promising therapeutic approach based on the concept of the gut-liver axis in liver disease. There has been an increase in the number of pre-clinical and clinical studies evaluating FMT in NAFLD treatment, however, existing findings diverge on its effects. Herein, we briefly summarized the mechanism of FMT for NAFLD treatment, reviewed randomized controlled trials for evaluating its efficacy in NAFLD, and proposed the prospect of future trials on FMT.
非酒精性脂肪性肝病 (NAFLD) 患者的人群以及相关的晚期肝病预计将继续增加，因为目前尚无批准用于治疗的药物。粪菌移植 (FMT) 被认为是一种基于肝病的肠道-肝脏轴概念的新型有前途的治疗方法。越来越多的临床前和临床研究评估 FMT 在 NAFLD 治疗中的作用，但现有研究结果存在差异。本文简要总结了 FMT 治疗 NAFLD 的机制，综述了评估其在 NAFLD 中的疗效的随机对照试验，并对 FMT 的未来试验提出了展望。
